Clinical Trials

Carcinoma, Hepatocellular

NCT07537946 2026-04-17

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

400 enrolled

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT07518706 2026-04-09

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

60 enrolled

Carcinoma, Hepatocellular

NCT07495579 2026-03-27

REVIVE

146 enrolled

Carcinoma, Hepatocellular

NCT07493668 2026-03-25

FLEX-HCC

80 enrolled

Carcinoma, Hepatocellular

NCT07475026 2026-03-16

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

198 enrolled

Carcinoma, Hepatocellular

NCT07466225 2026-03-12

HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion

Not yet recruiting

150 enrolled

Carcinoma, Hepatocellular

NCT07460206 2026-03-10

PRELUDE

108 enrolled

Carcinoma, Renal Cell

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

30 enrolled

Cholangiocarcinoma

NCT07417501 2026-02-18

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

Phase NA Not yet recruiting

60 enrolled

Other solid neoplasm

Solid Tumors

NCT07417800 2026-02-18

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

1,000 enrolled

Carcinoma, Hepatocellular

NCT07412054 2026-02-17

BLP-HCC

234 enrolled

Carcinoma, Hepatocellular

NCT07384416 2026-02-04

Single-Arm Trial of QL1706, Lenvatinib, and Nab-Paclitaxel for Advanced Refractory Penile Cancer

47 enrolled

Penile Neoplasms

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

718 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

87 enrolled

Phase 1/2 Not yet recruiting

Adenocarcinoma, Uterine Cervical Neoplasms

NCT07282509 2025-12-15

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

116 enrolled

Advanced Hepatocellular Carcinoma (HCC)

NCT07277972 2025-12-11

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

36 enrolled

Carcinoma, Renal Cell

NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

450 enrolled

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

28 enrolled

Advanced Endometrial Cancer

NCT07263360 2025-12-04

Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Phase 2/3 Not yet recruiting

29 enrolled

BTC

NCT07177716 2025-09-17

Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer

120 enrolled

Phase 4 Not yet recruiting

Uterine Cervical Neoplasms

NCT07160361 2025-09-16

Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB

56 enrolled

Carcinoma, Hepatocellular

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Biliary Tract Neoplasms

NCT07131501 2025-08-20

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

48 enrolled

Phase NA Not yet recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT07077798 2025-07-22

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

234 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT07014150 2025-06-10

Neoadjuvant Therapy of iIparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

30 enrolled

Phase 4 Not yet recruiting

Carcinoma, Hepatocellular

NCT07010393 2025-06-08

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

335 enrolled

Head & Neck

Thyroid Neoplasms

NCT06984718 2025-05-22

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

120 enrolled